Dermavant Sciences Inc.

Many of China’s homegrown first-in-class drugs have had a hard time becoming rainmakers for their originators, with few becoming blockbusters in domestic or international sales terms. Since the first

Merger-and-acquisition activity in the biopharmaceutical sector fell off sharply during the third quarter, a second consecutive quarter of decline after the busy and high-spending Q4 2023 and Q1 2024,

Organon agreed to acquire Roivant Sciences subsidiary Dermavant Sciences Inc. on 18 September for $175m up front, which will add an approved psoriasis drug, Vtama (tapinarof cream 1%), to Organon

There were a few jitters as its target date of 7 July came and went but Arcutis Biotherapeutics, Inc. can breathe easy after the firm's topical skin formulation Zoryve received US approval for atopi